华邦健康(002004) - 2015 Q1 - 季度财报

Financial Performance - Revenue for Q1 2015 reached ¥1,513,780,374.73, an increase of 37.33% compared to ¥1,102,281,859.19 in the same period last year[8] - Net profit attributable to shareholders was ¥189,113,851.80, representing a 156.25% increase from ¥73,799,173.96 year-on-year[8] - Net profit excluding non-recurring items was ¥192,068,346.66, up 126.77% from ¥84,696,020.67 in the previous year[8] - Basic earnings per share doubled to ¥0.26 from ¥0.13, reflecting a 100% increase[8] - The company expects a net profit attributable to shareholders for the first half of 2015 to range between 314.9334 million yuan and 384.9186 million yuan, representing a year-on-year increase of 35.00% to 65.00%[19] Assets and Liabilities - Total assets increased by 13.95% to ¥15,461,069,405.52 from ¥13,568,148,001.41 at the end of the previous year[8] - Net assets attributable to shareholders rose by 29.23% to ¥7,205,704,422.25 from ¥5,575,699,526.16[8] - The balance of deferred income tax liabilities was 117.8495 million yuan, an increase of 54.4762 million yuan from the beginning of the year, mainly due to the acquisition of Baisheng Pharmaceutical[17] - The balance of prepayments as of March 31, 2015, was 87.4832 million yuan, an increase of 40.6209 million yuan from the beginning of the year, primarily due to the acquisition of Baisheng Pharmaceutical[16] - The company reported an increase in interest payable to 46.0362 million yuan as of March 31, 2015, up by 13.9423 million yuan from the beginning of the year, due to increased loans and the acquisition of Baisheng Pharmaceutical[16] Cash Flow - Cash flow from operating activities showed a negative net amount of ¥19,326,849.85, a decline of 109.66% compared to ¥200,136,338.45 in the same period last year[8] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,936[11] - The top shareholder, Chongqing Huibang Travel Industry Co., Ltd., held 13.28% of shares, totaling 100,066,682 shares[11] Business Operations - The company reported an increase in accounts receivable by ¥141,881,600 to ¥316,489,400, attributed to increased sales and the consolidation of Baisheng Pharmaceutical[15] - The company’s operating revenue for Q1 2015 was 1,513.7804 million yuan, attributed to stable growth across various business units and the addition of Baisheng Pharmaceutical[17] - Operating costs for Q1 2015 amounted to 1,056.5564 million yuan, driven by revenue growth and the inclusion of Baisheng Pharmaceutical[17] Development and Goodwill - As of March 31, 2015, the company reported a development expenditure balance of 4.7393 million yuan, a decrease of 2.5033 million yuan from the beginning of the year, primarily due to no new drug technology purchases during the reporting period[16] - The goodwill balance as of March 31, 2015, was 2,973.8441 million yuan, an increase of 1,295.5377 million yuan from the beginning of the year, mainly due to the acquisition of Baisheng Pharmaceutical during the reporting period[16] Financial Expenses - The financial expenses for Q1 2015 increased by 70.53% year-on-year, primarily due to the issuance of corporate bonds and increased loans[17] Securities Investments - The company did not hold any securities investments during the reporting period[20]